Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Other Non Operating Income (2016 - 2025)

Ani Pharmaceuticals (ANIP) has disclosed Other Non Operating Income for 15 consecutive years, with $1.9 million as the latest value for Q4 2025.

  • Quarterly Other Non Operating Income rose 240.35% to $1.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.9 million through Dec 2025, up 195.98% year-over-year, with the annual reading at $1.9 million for FY2025, 147.95% up from the prior year.
  • Other Non Operating Income hit $1.9 million in Q4 2025 for Ani Pharmaceuticals, up from $1.7 million in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $1.9 million in Q4 2025 to a low of -$2.7 million in Q4 2021.
  • Historically, Other Non Operating Income has averaged -$210888.9 across 5 years, with a median of -$47500.0 in 2022.
  • Biggest five-year swings in Other Non Operating Income: tumbled 5250.0% in 2021 and later skyrocketed 2076.14% in 2025.
  • Year by year, Other Non Operating Income stood at -$2.7 million in 2021, then skyrocketed by 98.44% to -$42000.0 in 2022, then soared by 400.0% to $126000.0 in 2023, then plummeted by 1193.65% to -$1.4 million in 2024, then soared by 240.35% to $1.9 million in 2025.
  • Business Quant data shows Other Non Operating Income for ANIP at $1.9 million in Q4 2025, $1.7 million in Q2 2025, and $198000.0 in Q1 2025.